Docosahexaenoic acid (DHA) has long been marketed as a brain-supporting supplement, but neuroscience reveals a fundamentally different reality. DHA comprises 40% of all polyunsaturated fatty acids in the brain and over 90% of brain omega-3 content—making it a structural foundation of neural tissue rather than a peripheral support molecule.
This distinction carries significant clinical implications. Research demonstrates that patients with major depressive disorder exhibit 22% lower DHA levels in the orbitofrontal cortex, with deficits reaching 32% in women compared to 16% in men. The molecular mechanism is equally compelling: DHA’s six double bonds create membrane fluidity that directly determines how quickly neuronal signaling proteins respond to neural signals. Understanding DHA as architecture rather than supplementation may reshape how clinicians approach brain health interventions.
Read the full article on GMJ Newsroom.
Was this article helpful?
GMJ Brief · Announcement
📰 Read the full article: Why DHA Is Not a Brain Supplement—It’s Brain Architecture →
